drugset / Trial / NCT00654446

IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin

NCT00654446

Phase 3 Completed 442 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the effects on the kidney of rosuvastatin and simvastatin in subjects with Fredrickson Type IIa \& Type IIb Dyslipidaemia

Timeline

Start
2002-09
Primary completion
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule
Comparator Simvastatin Small molecule

Indications